322 related articles for article (PubMed ID: 30816013)
1. Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.
Lee TC; Qian M; Mu L; Di Tullio MR; Graham S; Mann DL; Nakanishi K; Teerlink JR; Lip GYH; Freudenberger RS; Sacco RL; Mohr JP; Labovitz AJ; Ponikowski P; Lok DJ; Estol C; Anker SD; Pullicino PM; Buchsbaum R; Levin B; Thompson JLP; Homma S; Ye S;
ESC Heart Fail; 2019 Apr; 6(2):297-307. PubMed ID: 30816013
[TBL] [Abstract][Full Text] [Related]
2. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy.
Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Jensen HK; Nielsen JC
Europace; 2016 Mar; 18(3):413-9. PubMed ID: 26378089
[TBL] [Abstract][Full Text] [Related]
3. Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis.
Briongos-Figuero S; Estévez A; Luisa Pérez M; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Basterra N; Rodríguez A; Lozano I; Muñoz-Aguilera R
Int J Cardiol; 2019 Jan; 274():163-169. PubMed ID: 30206014
[TBL] [Abstract][Full Text] [Related]
4. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death.
Amara N; Boveda S; Defaye P; Klug D; Treguer F; Amet D; Perier MC; Gras D; Algalarrondo V; Bouzeman A; Piot O; Deharo JC; Fauchier L; Babuty D; Bordachar P; Sadoul N; Marijon E; Leclercq C;
Europace; 2018 Jan; 20(1):65-72. PubMed ID: 28082419
[TBL] [Abstract][Full Text] [Related]
5. Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar.
Gutman SJ; Costello BT; Papapostolou S; Voskoboinik A; Iles L; Ja J; Hare JL; Ellims A; Kistler PM; Marwick TH; Taylor AJ
Eur Heart J; 2019 Feb; 40(6):542-550. PubMed ID: 30107489
[TBL] [Abstract][Full Text] [Related]
6. Two-Year Outcomes of Primary Prophylactic Use of Defibrillators for Ischemic and Non-Ischemic Cardiomyopathy - Propensity Score-Matched Analysis From the Nippon Storm Study.
Kondo Y; Noda T; Takanashi Y; Sasaki S; Sato Y; Nitta T; Aizwa Y; Ohe T; Kurita T
Circ J; 2024 Jun; 88(7):1107-1114. PubMed ID: 38057099
[TBL] [Abstract][Full Text] [Related]
7. Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia.
Evonich RF; Maheshwari A; Gardiner JC; Khasnis A; Kantipudi S; Ip JH; Grimes D; Hayter G; Thakur RK
J Interv Card Electrophysiol; 2004 Aug; 11(1):59-65. PubMed ID: 15273456
[TBL] [Abstract][Full Text] [Related]
8. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation.
Higgins AY; Bjerre J; Parzynski CS; Minges KE; Ahmad T; Desai NR; Enriquez A; Spatz ES; Friedman DJ; Curtis JP; Hlatky MA; Freeman JV
Am J Cardiol; 2020 Oct; 133():116-125. PubMed ID: 32862971
[TBL] [Abstract][Full Text] [Related]
10. Cardioverter-defibrillator reduces mortality risk in eligible ischemic and non-ischemic cardiomyopathy patients: Sub-analysis of the multi-center Improve SCA study.
Singh B; Hsieh YC; Liu YB; Lin KH; Joung B; Rodriguez DA; Chasnoits AR; Huang D; Zhang S; O'Brien JE; Lexcen DR; Cerkvenik J; Van Dorn B; Ching CK
Indian Heart J; 2023; 75(2):115-121. PubMed ID: 36736459
[TBL] [Abstract][Full Text] [Related]
11. Ambulatory blood pressure monitoring, 2D-echo and clinical variables relating to cardiac events in ischaemic cardiomyopathy following cardioverter-defibrillator implantation.
Antonini L; Pasceri V; Mollica C; Ficili S; Poti G; Aquilani S; Santini M; La Rocca S
J Cardiovasc Med (Hagerstown); 2011 May; 12(5):334-9. PubMed ID: 21487343
[TBL] [Abstract][Full Text] [Related]
12. Differences in mode of death between men and women receiving implantable cardioverter-defibrillators or cardiac resynchronization therapy in the MADIT trials.
Tompkins CM; Zareba W; Greenberg H; Goldstein R; McNitt S; Polonsky B; Brown M; Kutyifa V
Heart Rhythm; 2023 Jan; 20(1):39-45. PubMed ID: 36007729
[TBL] [Abstract][Full Text] [Related]
13. The Addition of a Defibrillator to Resynchronization Therapy Decreases Mortality in Patients With Nonischemic Cardiomyopathy.
Doran B; Mei C; Varosy PD; Kao DP; Saxon LA; Feldman AM; DeMets D; Bristow MR
JACC Heart Fail; 2021 Jun; 9(6):439-449. PubMed ID: 33992570
[TBL] [Abstract][Full Text] [Related]
14. Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%.
Al-Khatib SM; Hellkamp AS; Fonarow GC; Mark DB; Curtis LH; Hernandez AF; Anstrom KJ; Peterson ED; Sanders GD; Al-Khalidi HR; Hammill BG; Heidenreich PA; Hammill SC
JAMA; 2014 Jun; 311(21):2209-15. PubMed ID: 24893088
[TBL] [Abstract][Full Text] [Related]
15. Impact of T wave amplitude in lead aVR on predicting cardiac events in ischemic and nonischemic cardiomyopathy patients with an implantable cardioverter defibrillator.
Tanaka Y; Konno T; Tamura Y; Tsuda T; Furusho H; Takamura M; Sakata K; Yamagishi M; Hayashi K
Ann Noninvasive Electrocardiol; 2017 Nov; 22(6):. PubMed ID: 28440568
[TBL] [Abstract][Full Text] [Related]
16. Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy.
Higgins AY; Annapureddy AR; Wang Y; Minges KE; Bellumkonda L; Lampert R; Rosenfeld LE; Jacoby DL; Curtis JP; Miller EJ; Freeman JV
Am Heart J; 2022 Apr; 246():21-31. PubMed ID: 34968442
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women.
Zeitler EP; Hellkamp AS; Schulte PJ; Fonarow GC; Hernandez AF; Peterson ED; Sanders GD; Yancy CW; Al-Khatib SM
Circ Heart Fail; 2016 Jan; 9(1):e002630. PubMed ID: 26758365
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes after prophylactic ICD and CRT-D implantation in nonischemic patients: Analysis from a nationwide database of daily remote-monitoring transmissions.
Forleo GB; Solimene F; Pisanò EC; Zanotto G; Calvi V; Pignalberi C; Maglia G; Iacopino S; Quartieri F; Biffi M; Caravati F; Curnis A; Capucci A; Senatore G; Santamaria M; Della Bella P; Manzo M; Giacopelli D; Gargaro A; D'Onofrio A
J Cardiovasc Electrophysiol; 2019 Sep; 30(9):1626-1635. PubMed ID: 31165517
[TBL] [Abstract][Full Text] [Related]
19. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
Nakhoul GN; Schold JD; Arrigain S; Harb SC; Jolly S; Wilkoff BL; Nally JV; Navaneethan SD
Clin J Am Soc Nephrol; 2015 Jul; 10(7):1119-27. PubMed ID: 26111859
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Magnetic Resonance to Predict Appropriate Implantable Cardioverter Defibrillator Therapy in Ischemic and Nonischemic Cardiomyopathy Patients Using Late Gadolinium Enhancement Border Zone: Comparison of Four Analysis Methods.
Jablonowski R; Chaudhry U; van der Pals J; Engblom H; Arheden H; Heiberg E; Wu KC; Borgquist R; Carlsson M
Circ Cardiovasc Imaging; 2017 Sep; 10(9):. PubMed ID: 28838961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
